ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT)
ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT) Basic information
- Product Name:
- ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT)
- Synonyms:
-
- H-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-ILE-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-OH
- AURICULIN A, RAT
- ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT)
- ATRIAL NATRIURETIC PEPTIDE (4-27), RAT
- atrialnatriureticfactor(8-33
- atrial natriuretic peptide*fragment 4-27 rat
- Auriculin A
- ANP (126-149) (RAT)
- CAS:
- 91421-87-3
- MF:
- C104H168N38O33S2
- MW:
- 2542.81
- Product Categories:
-
- Peptide
- Mol File:
- 91421-87-3.mol
ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT) Chemical Properties
- Density
- 1.56
- storage temp.
- -15°C
ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT) Usage And Synthesis
Uses
Auriculin A is a synthetic atrial?natriuretic?factor?(ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits[1][2].
in vivo
Auriculin A (0.3 μg/min/kg; i.v.; for 30 min) antagonizes renal vasoconstriction in the dog[1].
Auriculin A (2 μg/kg prime, 0.2 μg/kg/min; i.v.; for 45 min) influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits[2].
| Animal Model: | Female mongrel dogs used in early clamp experiments (15-20 kg, anesthetized with 30 mg/kg pentobarbital sodium i.v.)[1] |
| Dosage: | 0.3 μg/min/kg |
| Administration: | Intravenous injection; last for 30 min |
| Result: | Increased glomerular filtration rate (GFR) 16±4% and Na excretion (UNa V) 261±63%, whereas it decreased urine osmolality (Uosm) 36±7% without changing free water clearance. Also increased diuresis (V) and kaliuresis (UKV). |
| Animal Model: | New Zealand white male rabbits (3-3.5 kg, anesthetized with 50 mg/kg Chloralose (HY-B1020) and 500 mg/kg Urethane (HY-B1207) i.v.)[2] |
| Dosage: | 0.5 μg/kg prime, 0.05 μg/kg/min; 2 μg/kg prime, 0.2 μg/kg/min; 4 μg/kg prime, 0.4 μg/kg/min; 8 μg/kg prime, 0.8 μg/kg/min |
| Administration: | Intravenous injection; last for 30-60 min |
| Result: | Significantly reduced mean blood pressure and increased mean perfusion pressure at 4 μg/kg prime, 0.4 μg/kg/min dose, while heart rate did not change. |
References
[1] Sosa RE, et al. Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am J Physiol. 1986 Mar;250(3 Pt 2):F520-4. DOI:10.1152/ajprenal.1986.250.3.F520
[2] Volpe M, et al. Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit. Circ Res. 1987 May;60(5):747-55. DOI:10.1161/01.res.60.5.747
ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT)Supplier
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 0551-65326643 18156095617
- info@cellmano.com
- Tel
- 21-619849051-1 18521059765
- synchempharma@aliyun.com
ATRIAL NATRIURETIC PEPTIDE (126-149) (RAT)(91421-87-3)Related Product Information
- GIP (3 - 42), human
- NEUROPEPTIDE W-30 (HUMAN)
- H-SER-LYS-PRO-ASP-ASN-PRO-GLY-GLU-ASP-ALA-PRO-ALA-GLU-ASP-MET-ALA-ARG-TYR-TYR-SER-ALA-LEU-ARG-HIS-TYR-ILE-ASN-LEU-ILE-THR-ARG-GLN-ARG-TYR-NH2
- H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH
- NEUROPEPTIDE Y (13-36), HUMAN, RAT
- ADRENOMEDULLIN (26-52) (HUMAN)
- ALA-ALA-ALA-ALA-ALA
- N-ALPHA-ACETYL-L-ARGININE
- L-Arginine acetate
- AC-ALA-ALA-ALA-ALA-OH
- AC-DL-ARG-OH 2H2O
- H-VAL-BETA-ALA-OH
- AC-ILE-NH2
- H-ALA-ARG-OH
- N-ACETYL-ALA-ALA-ALA
- AC-ASP-NH2
- GLY-GLY-ARG ACETATE SALT
- AC-GLN-NH2